Frequently Asked Questions

---

Zepbound and Ozempic are both medications belonging to the class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used in the management of type 2 diabetes and, more recently, in the treatment of obesity. While they share similarities in their mechanisms of action, there are notable differences between the two drugs. Zepbound, a newer GLP-1 RA, exhibits dual agonism at the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, resulting in enhanced glycemic control and weight loss. In contrast, Ozempic primarily targets the GLP-1 receptor, exerting potent effects on glucose metabolism and appetite regulation. Additionally, Zepbound has demonstrated superior efficacy in reducing both HbA1c levels and body weight compared to Ozempic in clinical trials.

 We are prepared to contact your insurance provider to inquire about coverage for your prescribed medication. Should you be covered by insurance for Zepbound or Wegovy, we are happy to prescribe this medication and continue to monitor your weight loss progress for a fee.

Yes. Laboratory work will need to be ordered and reviewed prior to starting these medications to ensure you can tolerate them. This will be ordered through Quest diagnostics. 

No. This is a one-time fee that is charged for creating your patient chart and setting up your account.